Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial
Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma. “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states. No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks. Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study…
